Thirty Years in the Making: The Approval of Lifileucel for Metastatic Melanoma

Oncology Data Advisor

Following the recent approval of lifileucel for unresectable or metastatic melanoma—the first cellular therapy to receive an approval for solid tumors—Matthew Hadfield, DO, member of the Oncology Data Advisor Fellows Forum and third-year Fellow at Brown University, sat down with Richard Carvajal, MD, Oncology Data Advisor Editorial Board Member and the Deputy Physician-in-Chief at the Northwell Health Cancer Institute, to discuss the significance of this approval, what it means for the treatment landscape of melanoma, and what to look forward to for the future of treating melanoma.